TransMedics Group, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2025: 16.93%

TransMedics Group, Inc. EBITDA Margin is 16.93% for the Trailing 12 Months (TTM) ending March 31, 2025, a 418.30% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.
  • TransMedics Group, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2024 was 3.27%, a -119.88% change year over year.
  • TransMedics Group, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2023 was -16.43%, a -83.97% change year over year.
  • TransMedics Group, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2022 was -102.47%, a 15.93% change year over year.
  • TransMedics Group, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2021 was -88.39%, a -21.56% change year over year.
Key Data
Date EBITDA Margin Net Income Margin EBT Margin Operating Income Margin